No abstract available.

No abstract available.
Carcinoma, Renal Cell* ; Survival Rate*

No abstract available.
Laser Coagulation* ; Prostatic Hyperplasia*

No abstract available.
Carcinoma, Renal Cell*

No abstract available.
Carcinoma, Renal Cell*

The patient with metastatic renal cell carcinoma at the time of presentation have an average survival of approximately 4 months, and only 10% can be expected to survive 1 year. The treatment of metastatic renal cell carcinoma remains a major public health problem in clinical medicine. Hormonal therapies, including progestational agents, and chemotherapies as single agent or in combinations seldom result in objective tumor regression or prolongation of survival and the response are usually temporary. Immunotherapic approaches to this tumor has not demonstrated a clear impact on growth of the tumor. But alpha-interferon therapy that initiated by deKernion produced 16. 5% response rate. The following results and conclusions are obtained with combination therapy such as a-interferon. nitrosourea, vinblastine and medroxyprogesteron acetate in metastatic renal cell carcinoma. 1. From March 1988 to August 1989, 15 patients with metastatic renal cell carcinoma were studied. Average patient age was 49.3 years. There was 11 men and 4 women. The disease was confined to lung in 46.7% of the patients and a Karnofsky performance status (PS) of 100 was identified in 7%: 13.3 % had PS score <70. 2. Of 15 patients, 4(26.7%) had a complete responses, 1 (6.7%) had a partial response, 3 (20.0%) had a minimal response and 7 (46.7%) had progression with no evidence of response to treatment. Of patients with pulmonary metastases alone, 5 (71.4%) had objective response or stabilization of disease and 2 (28.6%) had progression with no evidence of response to treatment. 1 (100.0%) patient with PS of 100 had partial response and no patients with PS<70 had response to therapy. 3. Median duration of survival in the overall subjects was 47 weeks : nonresponders survived for median of 21 weeks. Median duration of survival in nonresponders with pulmonary metastasis alone was 20 weeks. All responders are alive at least 33 weeks later. 4. The most common side effects were constitutional symptoms (73.3%). Hematologic toxicity (60%), gastrointestinal toxicity (40%), hepatic toxicity (26.7%) and nephrotoxicity (6.7%) occurred. Severe toxicity was noted only in 1 patient. 5. Natural killer cell activity in responders was 35.4 % and in nonresponders was 43.0%. Increased natural killer cell in responders was noted after treatment. T Lymphocyte subletting (T3 : cytotoxic T cell, T4 : helper T cell, T8 : suppressor T cell) performed at peritreatment had no statistic significance.In spite of short-term study, combination therapies includirrg alpha-interferon cause objective more regression and prolongation of survival. Futher trial with these regimens seem warranted in the management of metastatic renal cell carcinoma.
Carcinoma, Renal Cell* ; CD8-Positive T-Lymphocytes ; Clinical Medicine ; Drug Therapy ; Female ; Humans ; Interferon-alpha* ; Karnofsky Performance Status ; Killer Cells, Natural ; Lung ; Lymphocytes ; Male ; Neoplasm Metastasis ; Progestins ; Public Health ; Vinblastine

Palliative endourologic treatment was done in 94 cases for ureteral obstruction secondary to advanced malignancy The average survival was 4.2 months. The obstruction were caused by metastases or invasion of cancer in all patients. First we tried to insert a double J stent(STENT), when it failed percutaneous nephrostomy(PCN) was performed. Initially 16 patients were treated by STENT and 8 patients by PCN. The SIENT was changed 2.2 times on the average in all patients. 75% of the patients who had been treated by STENT experienced only one or two times of STENT changes before dying. Patency period of the STENT was 57.6 days on the average. The patency period was shorter in the patients who showed gross hematuria at the time of STENT insertion. Although survival was not so long, 60.6% patients were able to return to their homes. The endourologic management of the upper urinary tract obstruction will play a more important role and offer a better quality of life for end stage cancer patients.
Hematuria ; Humans ; Neoplasm Metastasis ; Pregnenolone Carbonitrile ; Quality of Life ; Stents ; Ureteral Obstruction ; Urinary Tract*

Malignant lymphoma of testis is rare, comprising 5% of all testicular tumor, but it is the most common type of testicular tumor in patients more than 5 years old. And malignant lymphoma of urinary bladder is extremely rare, while the majority of the affected patients fall within the to 60 age 40 group and is more common in female. Prognosis of the testicular lymphoma is very poor, and the interval free of disease is short and 9O % of patients die of generalized lymphoma within 2 years. Although in contrast to other nonepithelial malignant tumor, primary lymphoma of bladder carries a relatively favorable prognosis but secondary or disseminated bladder lymphoma has poor prognosis. This report concerns a case of simultaneous involvement of both testes and bladder by malignant lymphoma, which was treated with bilateral radical orchiectomy, transurethral resection of bladder and anticancer chemotherapy.
Child, Preschool ; Drug Therapy ; Female ; Humans ; Lymphoma* ; Orchiectomy ; Prognosis ; Testis ; Urinary Bladder

A clinical observation was made on patients with benign prostatic hyperplasia who had been admitted to the department of urology, Kyungpook National University Hospital during 10 years period from January, 1973 to December, 1982.The results were as follows:1. Out of 2252 total hospital admission, 184 were due to benign prostatic hyperplasia, giving rate of 8.1% to total and 31.8% male patients 50 years old or above, The most commonly involved age group was the 8th decade(47.8%) and mean age of total was 71.8 years old.2. The most frequent presenting symptom was acute urinary retention(37.5%), followed by dysuria(43.3%) and frequency(13.0%).3. The most common amount of residual urine was 200 to 300 ml group in 59 cases(32.1%), and 1000 ml or more was checked in 11(6.0%) and mean amount of total residual urine was 380 ml.4. In urinalysis, pyuria was checked in 71 cases(38.6%) and hematuria in 95(51.6%). In blood chemistry, BUN was elevated above normal levels in 21 cases and creatinine in 9. In urine culture, 30patients revealed positive bacterial culture.5. In IVP findings performed in 114 cases, the common finding was the indentation of bladder margin(81.6%), followed in frequency by elevated bladder base(58.3%). In endoscopic findings performed in 111 cases, the most common finding was trabeculation(93.7%), followed in order offrequency by inflammation(82.9%) and kissing signs of lateral lobes(68.5%).6. The another disease was associated with BHP in 101 cases (non-urologic disease in 61 and another disease in 40). The most common associated disease out of 101 cases with associated diseases was pulmonary tuberculosis in 22 and by next order hypertension in 10.7. Treatment modality was conservative indwelling catheterization in 115 cases(62.5%) and operation in 69(37.5%). In operative management, the most common approach was retropubic prostatectomy in 34 cases followed by suprapubic prostatectomy in 23 and TUR in 6.
Catheters, Indwelling ; Chemistry ; Creatinine ; Gyeongsangbuk-do ; Hematuria ; Humans ; Hypertension ; Male ; Middle Aged ; Prostatectomy ; Prostatic Hyperplasia* ; Pyuria ; Tuberculosis, Pulmonary ; Urinalysis ; Urinary Bladder ; Urology

Liposarcoma of the spermatic cord is very rare and preoperative diagnosis is difficult. Well differentiated liposarcoma is in general less aggressive than other type of liposarcoma and seldom metastasizes. Radical orchiectomy with wide local excision appear to be adequate treatment modality and offer better prognosis. We report a case of well differentiated liposarcoma in 51-year-old male with brief review of the literatures.
Diagnosis ; Humans ; Liposarcoma* ; Male ; Middle Aged ; Orchiectomy ; Prognosis ; Spermatic Cord*